(Q28244205)

English

Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients

scientific article (publication date: 18 July 2014)

In more languages

Statements

scholarly article

0 references

14 references

5 September 2019

9 September 2019

17 September 2019

2 October 2019

7 November 2019

8 November 2019

18 November 2019

19 November 2019

27 November 2019

28 November 2019

18 December 2020

24 January 2021

1 February 2021

17 January 2024

1 reference

based on heuristic

inferred from title

Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients (English)

0 references

0 references

0 references

1 reference

5 September 2019

1 reference

9 September 2019

heterocyclic compound

1 reference

17 September 2019

mechanism of action

1 reference

2 October 2019

carboxylic acid

1 reference

7 November 2019

1 reference

8 November 2019

1 reference

7 November 2019

1 reference

18 November 2019

1 reference

19 November 2019

1 reference

27 November 2019

transport protein

1 reference

28 November 2019

1 reference

based on heuristic

inferred from title

circulatory system

1 reference

based on heuristic

inferred from title

cholesteryl ester transfer protein

2 references

18 December 2020

1 February 2021

anticholesteremic agents

1 reference

18 December 2020

1 reference

24 January 2021

1 reference

based on heuristic

inferred from title

author name string

Daniel Keene

1

0 references

Clare Price

2

0 references

Matthew J Shun-Shin

3

0 references

Darrel P Francis

4

0 references

language of work or name

0 references

publication date

18 July 2014

14 references

5 September 2019

9 September 2019

17 September 2019

2 October 2019

7 November 2019

8 November 2019

18 November 2019

19 November 2019

27 November 2019

28 November 2019

18 December 2020

24 January 2021

1 February 2021

17 January 2024

14 references

5 September 2019

9 September 2019

17 September 2019

2 October 2019

7 November 2019

8 November 2019

18 November 2019

19 November 2019

27 November 2019

28 November 2019

18 December 2020

24 January 2021

1 February 2021

17 January 2024

349

0 references

jul18 2

0 references

g4379

0 references

copyright license

Creative Commons Attribution-NonCommercial 3.0 Unported

14 references

Europe PubMed Central

5 September 2019

Europe PubMed Central

9 September 2019

Europe PubMed Central

17 September 2019

Europe PubMed Central

2 October 2019

Europe PubMed Central

7 November 2019

Europe PubMed Central

8 November 2019

Europe PubMed Central

18 November 2019

Europe PubMed Central

19 November 2019

Europe PubMed Central

27 November 2019

Europe PubMed Central

28 November 2019

Europe PubMed Central

18 December 2020

Europe PubMed Central

24 January 2021

Europe PubMed Central

1 February 2021

Europe PubMed Central

17 January 2024

Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4103514

20 March 2017

Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4103514

20 March 2017

Effect of torcetrapib on the progression of coronary atherosclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4103514

20 March 2017

Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4103514

20 March 2017

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4103514

7 April 2017

Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4103514

7 April 2017

Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4103514

7 April 2017

Effects of torcetrapib in patients at high risk for coronary events

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4103514

7 April 2017

Intensive versus moderate lipid lowering with statins after acute coronary syndromes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4103514

7 April 2017

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4103514

7 April 2017

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4103514

24 May 2017

Mortality from ischaemic heart disease by country, region, and age: statistics from World Health Organisation and United Nations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4103514

29 September 2017

Effects of dalcetrapib in patients with a recent acute coronary syndrome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4103514

29 September 2017

Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4103514

29 September 2017

Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4103514

29 September 2017

Should both HDL-C and LDL-C be targets for lipid therapy? A review of current evidence

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4103514

29 September 2017

Effects of combination lipid therapy in type 2 diabetes mellitus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4103514

29 September 2017

Intensive statin therapy in acute coronary syndromes and stable coronary heart disease: a comparative meta-analysis of randomised controlled trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4103514

29 September 2017

Bezafibrate in men with lower extremity arterial disease: randomised controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4103514

29 September 2017

Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins: an idea whose time for testing is coming, part I.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4103514

29 September 2017

Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4103514

29 September 2017

Secondary preventive potential of lipid-lowering drugs. The Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4103514

29 September 2017

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4103514

29 September 2017

High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4103514

29 September 2017

High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4103514

29 September 2017

Removing the hype from hypertension

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4103514

2 June 2018

Safety of anacetrapib in patients with or at high risk for coronary heart disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4103514

2 June 2018

Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4103514

2 June 2018

Diabetes Intervention Study. Multi-intervention trial in newly diagnosed NIDDM.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4103514

2 June 2018

Combined use of extended-release niacin and atorvastatin: safety and effects on lipid modification

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4103514

27 November 2018

Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4103514

27 November 2018

A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4103514

27 November 2018

Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with sta

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4103514

27 November 2018

Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts

1 reference

https://pubmed.ncbi.nlm.nih.gov/25038074

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lipids and risk of coronary heart disease. The Framingham Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/25038074

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study

1 reference

https://pubmed.ncbi.nlm.nih.gov/25038074

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/25038074

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Primary prevention of ischaemic heart disease: WHO coordinated cooperative trial. A summary report

1 reference

https://pubmed.ncbi.nlm.nih.gov/25038074

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Trial of clofibrate in the treatment of ischaemic heart disease. Five-year study by a group of physicians of the Newcastle upon Tyne region

1 reference

https://pubmed.ncbi.nlm.nih.gov/25038074

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B

1 reference

https://pubmed.ncbi.nlm.nih.gov/25038074

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The treatment of cerebrovascular disease with clofibrate. Final report of the Veterans Administration Cooperative Study of Atherosclerosis, Neurology Section

1 reference

https://pubmed.ncbi.nlm.nih.gov/25038074

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ischaemic heart disease: a secondary prevention trial using clofibrate. Report by a research committee of the Scottish Society of Physicians

1 reference

https://pubmed.ncbi.nlm.nih.gov/25038074

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Controlled trial of clofibrate in cerebral vascular disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/25038074

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid

1 reference

https://pubmed.ncbi.nlm.nih.gov/25038074

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clofibrate and niacin in coronary heart disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/25038074

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy of Gemfibrozil in Dyslipidaemic Subjects with Suspected Heart Disease. An Ancillary Study in the Helsinki Heart Study Frame Population

1 reference

https://pubmed.ncbi.nlm.nih.gov/25038074

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/25038074

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport

1 reference

https://pubmed.ncbi.nlm.nih.gov/25038074

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1136/BMJ.G4379

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28244205&oldid=2056122667"